 BRISBANE, Calif.--BUSINESS WIRE--Sangamo Therapeutics, Inc. Nasdaq: SGMO, a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott will lead clinical strategy across all phases of development and regulatory approval and will report to Sandy Macrae, Sangamos Chief Executive Officer. Sangamo also announced today that, effective January 1, 2021, Jason Fontenot, PhD, has been promoted to Chief Scienti 